874831-60-4 Usage
Uses
Used in Pharmaceutical Research and Synthesis:
(3-PIPERAZIN-1-YL-PROPYL)-CARBAMIC ACID TERT-BUTYL ESTER is used as an intermediate in the synthesis of various pharmaceutical drugs due to its unique chemical structure and reactivity.
Used in Organic Reactions:
In the field of organic chemistry, (3-PIPERAZIN-1-YL-PROPYL)-CARBAMIC ACID TERT-BUTYL ESTER is utilized as a catalyst to facilitate specific reactions, enhancing the efficiency and selectivity of the processes.
Used in Therapeutic Agent Development:
(3-PIPERAZIN-1-YL-PROPYL)-CARBAMIC ACID TERT-BUTYL ESTER has been studied for its potential as a therapeutic agent, indicating its broad applications in the treatment of various diseases, although specific applications would require further research and clinical validation.
Used in Laboratory Settings:
The stability and protective nature of the tert-butyl ester group allow (3-PIPERAZIN-1-YL-PROPYL)-CARBAMIC ACID TERT-BUTYL ESTER to be easily manipulated in laboratory settings, making it a valuable tool for researchers in the development of new chemical entities and pharmaceuticals.
Check Digit Verification of cas no
The CAS Registry Mumber 874831-60-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,7,4,8,3 and 1 respectively; the second part has 2 digits, 6 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 874831-60:
(8*8)+(7*7)+(6*4)+(5*8)+(4*3)+(3*1)+(2*6)+(1*0)=204
204 % 10 = 4
So 874831-60-4 is a valid CAS Registry Number.
InChI:InChI=1/C12H25N3O2/c1-12(2,3)17-11(16)14-5-4-8-15-9-6-13-7-10-15/h13H,4-10H2,1-3H3,(H,14,16)
874831-60-4Relevant academic research and scientific papers
COMPOSITIONS AND METHODS FOR THE TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS
-
Page/Page column 337, (2020/12/30)
Compositions and methods for the treatment of viral infections include conjugates containing inhibitors of viral gp120 receptor (e.g., temsavir, BMS-818251, DMJ-ll-121, BNM-IV-147, or analogs thereof) linked to an Fc monomer, an Fc domain, and Fc-binding peptide, an albumin protein, or albumin- binding peptide. In particular, conjugates can be used in the treatment of viral infections (e.g., HIV infections).
SUBSTITUTED PYRIDINES AS INHIBITORS OF DNMT1
-
, (2018/01/20)
The invention is directed to substituted pyridine derivatives. Specifically, the invention is directed to compounds according to Formula (Iar): (Iar) wherein Yar, X1ar, X2ar, R1ar, R2ar, R3ar, R4ar and R5ar are as defined herein; or a pharmaceutically acceptable salt or prodrug thereof. The compounds of the invention are selective inhibitors of DNMT1 and can be useful in the treatment of cancer, pre-cancerous syndromes, beta hemoglobinopathy disorders, sickle cell disease, sickle cell anemia, and beta thalassemia, and diseases associated with DNMT1 inhibition. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting DNMT1 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.
